- Home
- FLC vs FENC Comparison
FLC vs FENC Comparison
Compare FLC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- FENC
- Stock Information
- Founded
- FLC 2003
- FENC 1996
- Country
- FLC United States
- FENC United States
- Employees
- FLC N/A
- FENC N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLC Finance
- FENC Health Care
- Exchange
- FLC Nasdaq
- FENC Nasdaq
- Market Cap
- FLC 176.2M
- FENC 156.9M
- IPO Year
- FLC N/A
- FENC 2001
- Fundamental
- Price
- FLC $16.96
- FENC $6.65
- Analyst Decision
- FLC
- FENC Strong Buy
- Analyst Count
- FLC 0
- FENC 2
- Target Price
- FLC N/A
- FENC $14.00
- AVG Volume (30 Days)
- FLC 37.8K
- FENC 58.2K
- Earning Date
- FLC 01-01-0001
- FENC 03-20-2025
- Dividend Yield
- FLC 6.64%
- FENC N/A
- EPS Growth
- FLC N/A
- FENC N/A
- EPS
- FLC N/A
- FENC N/A
- Revenue
- FLC N/A
- FENC $49,348,000.00
- Revenue This Year
- FLC N/A
- FENC $170.43
- Revenue Next Year
- FLC N/A
- FENC $6.70
- P/E Ratio
- FLC N/A
- FENC N/A
- Revenue Growth
- FLC N/A
- FENC 278.09
- 52 Week Low
- FLC $12.62
- FENC $3.96
- 52 Week High
- FLC $15.45
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- FLC 55.02
- FENC 66.40
- Support Level
- FLC $16.80
- FENC $6.30
- Resistance Level
- FLC $17.08
- FENC $6.64
- Average True Range (ATR)
- FLC 0.21
- FENC 0.29
- MACD
- FLC 0.00
- FENC 0.06
- Stochastic Oscillator
- FLC 69.49
- FENC 90.23
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.